FDA OKs Medtronic's Intrinsic ICD (implantable cardioverter defibrillator):
This article was originally published in Clinica
Medtronic has gained US approval to sell its new implantable cardioverter-defibrillator (ICD), which is designed to promote natural heart activity and reduce unnecessary pacing in the right ventricle of the heart. The dual-chamber Intrinsic ICD uses a proprietary feature called Managed Ventricular Pacing (MVP), which enables the defibrillator to automatically adapt the way it paces. Unnecessary pacing has been shown to be harmful in some patients. The company plans to use the MVP feature in its future pacing and defibrillation products.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.